A 32-year-old G3P2 undergoes emergency cesarean delivery at 38 weeks for placenta previa. Intraoperatively, the lower segment is heavily infiltrated with placental tissue. After delivery of the infant and placenta, continuous oozing from the placental bed persists despite adequate uterine contraction and two doses of oxytocin. Estimated blood loss is 1200 mL. Vital signs: BP 92/58 mmHg, HR 116/min. Hemoglobin is 7.8 g/dL. Coagulation profile: PT 18 sec (normal 12–14), aPTT 42 sec (normal 28–35), fibrinogen 180 mg/dL (normal 200–400). What is the most appropriate next intervention?

Explanation

## Clinical Diagnosis: Postpartum Hemorrhage with Coagulopathy ### Case Analysis: Placenta Previa with Abnormal Hemostasis **Key Point:** This patient has developed **consumptive coagulopathy** secondary to massive hemorrhage and transfusion. The combination of prolonged PT, aPTT, and low fibrinogen indicates disseminated intravascular coagulation (DIC) or dilutional coagulopathy, which must be corrected urgently to prevent further bleeding. ### Coagulation Abnormalities Explained | Parameter | Value | Normal | Interpretation | | --- | --- | --- | --- | | PT | 18 sec | 12–14 sec | ↑ (Factor II, V, VII, X deficiency) | | aPTT | 42 sec | 28–35 sec | ↑ (Factor VIII, IX, XI, XII deficiency) | | Fibrinogen | 180 mg/dL | 200–400 mg/dL | ↓ (Consumption/dilution) | | Hemoglobin | 7.8 g/dL | >10 g/dL | Severe anemia from blood loss | **High-Yield:** In obstetric hemorrhage, fibrinogen is the **first clotting factor to be depleted** and the last to recover. Maintain fibrinogen >100 mg/dL during active bleeding. ### Pathophysiology of Coagulopathy in PPH 1. **Massive hemorrhage** → loss of clotting factors and platelets 2. **Dilution** from crystalloid and RBC transfusion without FFP/cryoprecipitate 3. **Consumption** of factors in DIC (triggered by placental abruption, amniotic fluid embolism, or sepsis) 4. **Hypothermia & acidosis** → further impairment of coagulation ### Correction Strategy: Massive Transfusion Protocol ```mermaid flowchart TD A[PPH with Coagulopathy]:::outcome --> B[Check PT, aPTT, Fibrinogen, Platelets]:::action B --> C{Fibrinogen <150 mg/dL?}:::decision C -->|Yes| D[Cryoprecipitate 10 units]:::action C -->|No| E[FFP if PT/aPTT prolonged]:::action D --> F{PT/aPTT prolonged?}:::decision F -->|Yes| G[FFP 4 units]:::action F -->|No| H[Reassess in 15 min]:::action G --> I{Platelet count <50K?}:::decision I -->|Yes| J[Platelet transfusion]:::action I -->|No| K[Continue medical management]:::action ``` ### Why Cryoprecipitate + FFP is Correct **Cryoprecipitate 10 units:** - Contains fibrinogen (1.5–2.5 g per unit), Factor VIII, von Willebrand factor, fibronectin - **Rapidly corrects hypofibrinogenemia** (180 → ~250 mg/dL expected) - Each unit raises fibrinogen by ~10 mg/dL - Preferred over FFP for fibrinogen replacement (smaller volume, higher concentration) **Fresh Frozen Plasma 4 units:** - Contains all vitamin K–dependent factors (II, VII, IX, X) and others (V, VIII, XI, XII) - Corrects prolonged PT (Factor VII deficiency) and aPTT (Factor VIII/IX/XI/XII deficiency) - Each unit = 200–250 mL; 4 units provide ~1 g fibrinogen + all other factors **Clinical Pearl:** The **1:1:1 ratio** (RBC:FFP:Platelets) is recommended in massive transfusion protocols for trauma and obstetric hemorrhage to prevent dilutional coagulopathy. **Mnemonic: CRYOFIB** — **CRYOprecipitate for FIBrinogen** (when fibrinogen <100–150 mg/dL in active bleeding). [cite:ACOG Practice Bulletin #183; RCOG Massive Transfusion Guidelines]